These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12958068)

  • 1. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
    Stankovic T; Hubank M; Cronin D; Stewart GS; Fletcher D; Bignell CR; Alvi AJ; Austen B; Weston VJ; Fegan C; Byrd PJ; Moss PA; Taylor AM
    Blood; 2004 Jan; 103(1):291-300. PubMed ID: 12958068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
    Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
    Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
    Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
    Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
    Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
    Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATM mutations in sporadic lymphoid tumours.
    Stankovic T; Stewart GS; Byrd P; Fegan C; Moss PA; Taylor AM
    Leuk Lymphoma; 2002 Aug; 43(8):1563-71. PubMed ID: 12400598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
    Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
    J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
    Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
    Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
    Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
    Lin K; Adamson J; Johnson GG; Carter A; Oates M; Wade R; Richards S; Gonzalez D; Matutes E; Dearden C; Oscier DG; Catovsky D; Pettitt AR
    Clin Cancer Res; 2012 Aug; 18(15):4191-200. PubMed ID: 22675167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
    Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
    Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
    Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
    J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of interferon-stimulated genes by gamma-ray irradiation independently of the ataxia telangiectasia mutated-p53 pathway.
    Sugihara T; Murano H; Nakamura M; Ichinohe K; Tanaka K
    Mol Cancer Res; 2011 Apr; 9(4):476-84. PubMed ID: 21357441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionizing radiation can induce GSK-3beta phosphorylation and NF-kappaB transcriptional transactivation in ATM-deficient fibroblasts.
    Kwon O; Kim KA; He L; Kim SO; Kim MS; Cha EY; Yoon BD; Sok DE; Jung M; Ahn JS; Kim BY
    Cell Signal; 2008 Apr; 20(4):602-12. PubMed ID: 18243662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel induction of ATM-dependent pro- and antiapoptotic signals in response to ionizing radiation in murine lymphoid tissue.
    Rashi-Elkeles S; Elkon R; Weizman N; Linhart C; Amariglio N; Sternberg G; Rechavi G; Barzilai A; Shamir R; Shiloh Y
    Oncogene; 2006 Mar; 25(10):1584-92. PubMed ID: 16314843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New translocations in a case of atypical B-cell chronic lymphocytic leukemia: involvement of ATM, MLL, and TP53 genes.
    Collado R; Hueso J; Cabello AI; Oliver I; Egea M; Orero M; Miguel-Sosa A; Cigudosa JC; Benítez J; Barragán E; Carbonell F
    Cancer Genet Cytogenet; 2006 Sep; 169(2):176-8. PubMed ID: 16938579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.